Group 1 - The company, Huadong Medicine (000963.SZ), announced its participation as a limited partner in a new investment fund, "Hangzhou Fuguang Hongze Equity Investment Partnership (Limited Partnership)" [1] - The total committed capital for the fund is RMB 2 billion, with the company contributing RMB 980 million, representing a 49% stake [1] - The investment focus of the fund includes innovative pharmaceuticals, medical aesthetics, health and wellness, animal health, and other sectors related to biology, medicine, and health that align with Hangzhou's five major industrial ecosystems [1]

Core Viewpoint - China Resources Pharmaceutical (03320) is collaborating with partners to establish a fund with an expected scale of RMB 500 million, focusing on high-growth investments in synthetic biology, innovative drugs, and biotechnology sectors [1] Company Summary - The company plans to commit a total investment of up to RMB 123 million, which represents approximately 24.6% of the total committed capital for the fund [1] - The fund is expected not to be accounted as a subsidiary of the company after its establishment [1] - Shenzhen China Resources Capital is anticipated to be appointed as the fund manager [1]

Core Viewpoint - The agreement outlines the terms for the issuance of shares by Ruizhi Medical Technology Co., Ltd. to Jiangmen Ruilian Medical Investment Co., Ltd. for the year 2024, including share transfer and ownership changes [1][2][3]. Group 1: Share Issuance Agreement - The agreement was signed on April 1, 2025, between Ruizhi Medical Technology Co., Ltd. and Jiangmen Ruilian Medical Investment Co., Ltd. [1] - The total registered capital of Ruizhi Medical is RMB 497.96 million, with a total share count of 100% held by MEDICAL LIMITED [1]. - WOO SWEE LIAN, the actual controller, currently holds 5.11% of the shares, with an additional 4.56% held by MEGA STAR [1]. Group 2: Share Transfer and Ownership Changes - Following a court ruling, WOO SWEE LIAN and his associates will hold 15.70% of the shares after the forced transfer of 30,033,098 shares from another shareholder [2]. - After the completion of a share transfer agreement, WOO SWEE LIAN and his associates will collectively own 21.18% of the shares, maintaining his position as the controlling shareholder [3]. Group 3: Subscription Details - The agreement allows for the issuance of up to 60,019,704 shares, representing 30% of the total share capital prior to the issuance, at a price of RMB 5.27 per share [4][5]. - The subscription amount will be determined by the number of shares multiplied by the issuance price, with funds sourced legally by the subscriber [5]. - The shares subscribed will have a lock-up period of 18 months post-issuance [5]. Group 4: Legal and Compliance - The agreement is subject to approval from the board of directors and shareholders, as well as regulatory approval from the Shenzhen Stock Exchange and the China Securities Regulatory Commission [7]. - Any modifications to the agreement must be documented in writing and comply with legal procedures [7][8].